// App-Quantinova.ai

NDM02 : Long-Term Reduction in 48-Week Confirmed Disability Progression after 5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

Researchers

Presenter

  • Stephen L Hauser

Principal Investigators

  • Ludwig Kappos

  • Xavier Montalban

  • Amit Bar-Or

  • Gavin Giovannoni

  • Fabian Model

  • Stanislas Hubeaux

  • Lahar Mehta

  • Jerry S Wolinsky

Medical Centers

  • Perelman School of Medicine, University of Pennsylvania, Ardmore, PA

  • Division of Neurology, University of Toronto

  • Vall d'Hebron University Hospital...

  • University of California, San Francisco, CA

  • McGovern Medical School at the University of Texas Health Science Center, Houston, TX

  • University Hospital Basel, University of Basel

  • Queen Mary University, London, UK

Locations

  • United States

  • Canada

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • GC Vitamin D Binding Protein

Drug/Treatment

  • Ocrelizumab

  • IFN-lambda

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01247324

  • NCT01412333

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved